Enterprise AI Analysis
A Clinically Interpretable Deep CNN Framework for Early Chronic Kidney Disease Prediction Using Grad-CAM-Based Explainable AI
By Anas Bin Ayub, Nilima Sultana Niha, Md. Zahurul Haque
Executive Impact: Key Findings at a Glance
This analysis distills the core impact of the research into actionable insights for enterprise leaders.
0%
Classification Accuracy
0M+
Global CKD Patients
0M
Annual Chronic Disease Deaths
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
Problem & Context
Methodology & Innovation
Performance & Results
Strategic Implications & Future
Chronic Kidney Disease (CKD) is a global health crisis, affecting over 850 million individuals worldwide. It's a progressive condition leading to End-Stage Renal Disease (ESRD) and is often undiagnosed until advanced stages. Early and accurate diagnosis is critical for effective management and preventing severe health and economic consequences.
90%
Affected adults unaware of early CKD
This study proposes a novel deep Convolutional Neural Network (CNN) architecture designed for early CKD detection from CT kidney images. To address data imbalance, the Synthetic Minority Oversampling Technique (SMOTE) was applied. Crucially, interpretability is enhanced through Gradient-weighted Class Activation Mapping (Grad-CAM), providing visual explanations of the model's predictions and increasing clinical trustworthiness.
Enterprise Process Flow
Image Augmentation (Rescaling)
→
Color Space Conversion (BGR to RGB)
→
Label Encoding
→
Data Balancing (SMOTE)
→
Image Dimension Restoration
→
Train-Test Split (80/20)
→
Train-Validation Split (90/10)
The custom deep CNN model achieved outstanding classification performance, with 100% accuracy on both training and testing datasets for all four kidney classes (cyst, normal, stone, tumor). This model demonstrated robust discriminative capability, achieving perfect scores across precision, recall, F1-score, and AUC curves, as validated by a comprehensive confusion matrix and ROC analysis.
100%
Achieved Accuracy
| References | Dataset Size | Models Used | Accuracy |
|---|---|---|---|
| Md Nazmul Islam et al. [13] | 12,446 | Swin Transformer | 99.30% |
| Muneer Majid et al. [15] | 12,446 | ResNet-101, DenseNet-121 | 94.09% (both) |
| Chin-Chi Kuo et al. [22] | 4,505 | ResNet, AI-GFR model | 85.6% |
| Md. Arifuzzaman et al. [23] | 12,446 | Ensemble Method | 96% |
| Fatemeh Zabihollahy et al. [27] | 315 | CNN | 83.75% |
| Devrim Akgun et al. [28] | 460 | MobileNet, ResNet50 | 86.42% / 82.06% |
| Kalkan et al. [29] | 5000 | ResNet152V2 | 89.58% |
| Lee et al. [30] | 1596 | MobileNetV2, Inception V3, MobileNet | 88.80% / 74.3% / 72.37% |
| Our Work | 12,446 | Deep-CNN | 100% |
The proposed framework offers significant potential for enhancing clinical diagnostic workflows and improving early medical intervention strategies for CKD. Its high accuracy and interpretability make it a valuable tool for healthcare providers. Future work includes large-scale clinical integration, automated e-prescription generation, incorporation of additional clinical metadata (eGFR, age, blood pressure), and development of mobile/IoMT platforms for remote screening.
Projected ROI Calculator
Estimate the potential return on investment for implementing similar AI solutions in your enterprise.
Estimated Annual Savings
$0
Annual Hours Reclaimed
0
Your AI Implementation Roadmap
A phased approach to integrate this advanced AI capability into your operations and achieve measurable impact.
Phase 1: Model Integration & Pilot Deployment
Duration: 3-6 Months
Seamless integration of the AI model into existing clinical imaging systems and initial pilot programs to gather real-world performance data and user feedback.
Phase 2: Data Enrichment & System Expansion
Duration: 6-12 Months
Incorporating diverse clinical metadata (eGFR, age, blood pressure) and expanding the system to support automated e-prescription generation and broader diagnostic capabilities.
Phase 3: Multi-center Validation & Mobile Platform Development
Duration: 12-24 Months
Conducting extensive validation across multi-center, cross-hospital datasets and developing a mobile/IoMT-based platform for remote, point-of-care CKD screening.
Ready to Transform Your Operations with AI?
Connect with our AI strategists to explore how this research can be tailored to your specific enterprise needs and drive significant value.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat